Globalepolicy.org is a free to access global medical news service for the consumer, professional and researcher.


             
 

Background: A treatment algorithm and screening examination have been developed to guide patient management and prospectively determine potential for highly active individuals to succeed with nonoperative care after anterior cruciate ligament rupture.

Objective: To prospectively characterize and classify the entire population of highly active individuals over a 10-year period and provide final outcomes for individuals who elected nonoperative care.

Methods: Inclusion criteria included presentation within 7 months of the index injury and an International Knee Documentation Committee level I or II activity level before injury. Concomitant injury, unresolved impairments, and a screening examination were used as criteria to guide management and classify individuals as noncopers (poor potential) or potential copers (good potential) for nonoperative care.

Results: A total of 832 highly active patients with subacute anterior cruciate ligament tears were seen over the 10-year period; 315 had concomitant injuries, 87 had unresolved impairments, and 85 did not participate in the classification algorithm. The remaining 345 patients (216 men, 129 women) participated in the screening examination a mean of 6 weeks after the index injury. There were 199 subjects classified as noncopers and 146 as potential copers. Sixty-three of 88 potential copers successfully returned to preinjury activities without surgery, with 25 of these patients not undergoing anterior cruciate ligament reconstruction at the time of follow-up.

Conclusion: The classification algorithm is an effective tool for prospectively identifying individuals early after anterior cruciate ligament injury who want to pursue nonoperative care or must delay surgical intervention and have good potential to do so.



NAVIGATION


         

 

Fenwal, Inc., a global medical technology company focused on improving blood collection, separation, safety and availability, announced that the U.S. Food and Drug Administration has granted Fenwal 510(k) clearance to market its Amicus® blood cell separator for collecting human platelets stored in InterSol® platelet additive solution (PAS 3)…

 

CaridianBCT, a leading global provider of technology, products and services in automated blood collections, therapeutic apheresis and cell therapy systems, whole blood processes and pathogen reduction technologies announced it has received 510(k) clearance for the Trima Accel® Automated Blood Collection System Version 6…

 

On January 27, 2010 the FDA cleared the Haemonetics (NYSE: HAE) 510(k) for its expanded nomogram to collect two Red Blood Cells on the Cymbal® Automated Blood Collection System from female donors who are at least 150 pounds and are 63 inches in height…

 

BD Diagnostics, a segment of BD (Becton, Dickinson and Company), announced the launch of BD Microtainer® MAP Microtube for Automated Process for hematology testing…

 

US scientists have developed synthetic red blood cells that mimic the softness, flexibility and oxygen carrying-property of natural red blood cells, and can be used to deliver drugs and diagnostic agents…

 

US scientists have developed synthetic red blood cells that mimic the softness, flexibility and oxygen carrying-property of natural red blood cells, and can be used to deliver drugs and diagnostic agents…

 

Fenwal Inc., a global medical technology company focused on improving blood collection, separation, safety and availability, announced that the U.S. Food and Drug Administration has granted Fenwal approval to market InterSol® platelet additive solution…

 

Fenwal Inc., a global medical technology company focused on improving blood collection, separation, safety and availability, announced that the U.S. Food and Drug Administration has granted Fenwal approval to market InterSol® platelet additive solution…

 

Masimo (Nasdaq: MASI), the inventor of Pulse CO-Oximetry(TM) and Measure-Through Motion and Low-Perfusion pulse oximetry, announced that a new peer-reviewed clinical study published in this month’s Inhalation Toxicology demonstrates that Masimo Rainbow SET® Pulse CO-Oximetry (SpCO) provides reliable measurements of carbon monoxide (CO) in the blood that facilitate fast, accurate diagnosis of CO poisoning in pre-hospital emergency and rescue environments.

 

AdvanDx announced that it has received FDA 510(k) clearance for a fast, 90 minutes protocol for its E. faecalis/OE PNA FISH(®) test. The faster protocol reduces the PNA FISH turn-around time from the original 2.5 hours to 90 minutes by reducing PNA probe hybridization from 90 minutes to 30 minutes.




March 2010
Mon Tue Wed Thu Fri Sat Sun
« Feb    
1234567
891011121314
15161718192021
22232425262728
293031